Thursday, September 29
6 - 8 p.m. at ISB


Reimagine: Healthcare

ISB's Reimagine event is back! We're excited to welcome you to ISB for an evening of science, hors d'oeuvres and drinks.

Reimagine: Healthcare will focus on how we can revolutionize healthcare by empowering patients to participate in their own health and wellness. Learn how we’re improving patient treatments and outcomes by moving away from the bricks and mortar of hospitals. Join us in person on September 29 from 6 to 8 p.m. to find out more.

Reimagine is an annual event that is open to the community – learn about ISB's science and join others in supporting our research.

ISB lab

September 29


6 - 8 p.m.

Pacific Time

Garage Access

Available onsite


Our program will feature an exclusive pre-recorded conversation between ISB President, Dr. Jim Heath, Nobel laureate and distinguished immunologist, Dr. Jim Allison, and renowned cancer genomic scientist, Dr. Lynda Chin.

Jim Heath, PhD

Dr. Jim Heath is President and Professor at ISB. He has received several awards and honors, including the Irving Weinstein Award from the American Association of Cancer Researchers, and the Sackler Prize in the Physical Sciences. He was named one of the top seven innovators in the world by Forbes Magazine, and has founded or cofounded several companies, including PACT Pharma, Integrated Diagnostics, Indi Molecular, CTI Molecular Imaging (acquired by Siemens in 2005), Sofie Biosciences, Isoplexis, and NanoSys.

Jim Allison, PhD

Dr. Jim Allison is Regental Professor and Chair of the Department of Immunology, the Olga Keith Wiess Distinguished University Chair for Cancer Research, Director of the Parker Institute for Cancer Research, and the Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center. He has spent a distinguished career studying the regulation of T cell responses and developing strategies for cancer immunotherapy. He earned the 2018 Nobel Prize in Physiology or Medicine, which he shared with Dr. Tasuku Honjo, "for their discovery of cancer therapy by inhibition of negative immune regulation."

Lynda Chin, MD

Dr. Lynda Chin is an elected member of the National Academy of Medicine, a renowned cancer genomic scientist and a leader in application of technologies, AI and Machine Learning and big data in medicine. A dermatologist by training, Dr. Chin conducted research in cancer genomics and cancer biology at Dana Farber Cancer Institute and Harvard Medical School, served on the executive subcommittee of The Cancer Genome Atlas (TCGA) and co-led development of the Firehose pipeline at the Broad Institute.

Board Members

Special thank you to our foundation and governance board members.

Foundation Board:

Douglas Howe, Chairman of the Board
Marne Anderson
Suzie Burke
Kathryn Carole Ellison
Mary Duray
Barb Moe
Chris Moe
Ginny Ruffner
Brian Turner

Governance Board:

Charles Watts, MD, Chairman of the Board
David Sabey
Thomas Cable
Amy Compton-Phillips, MD
Stephen Graham
Douglas Howe
Daniel Ling
Craig Mundie
Roger Perlmutter, MD, PhD
Wasif Rasheed
Heather Redman
Brian Turner

Thank you to our sponsor:

Thompson Wellness Wealth Management, a member of D.A. Davidson and Co. Logo